Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Session includes invitee/speaker with CF. Others with CF encouraged to participate virtually.
Session includes invitee/speaker with CF. Others with CF encouraged to participate virtually.

PHARM
Workshop

W28--Innovations in CF Pharmacotherapy

Friday, September 27, 2024
10:15 AM - 12:15 PM ET
Location:157 A-C

Recorded Session

The session will look into the use of modulator therapy in special populations where data and dosing strategies are limited. Abstracts include assessing dose guidance in patients with hepatic disease or damage using pharmacokinetic modeling and provider surveys. Will also explore modulator use in pregnancy and postnatal care as well as modulator kinetics with significant drug interactions. The session will also include and abstract reviewing the impact of patients being required to use multiple pharmacies on medication access.

Learning Objectives:

  • Summarize the dosing stratagies for elexacaftor/tezacaftor/ivacaftor in patients with signficant drug-drug interactions or hepatic damage/disease.
  • Review the clinical practice of modulator use in pregnancy and postnatal care.
  • Identify the impact of filling at multiple pharmacies on medication position ration in pediatric patients.

Presentations:

  • 10:15 AM - 12:15 PM ET
    W28.1- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor Dosing Guidance in Cystic Fibrosis-associated Liver Disease using Physiologically-Based Pharmacokinetic (PBPK) Modeling

    Speaker: Alan Shi – University of Southern California Mann School of Pharmacy

  • 10:15 AM - 12:15 PM ET
    W28.2- Impact of Number of Pharmacies on Dornase alfa Medication Possession Ratio in Children with Cystic Fibrosis

    Speaker: Hilary M. Vogt, PharmD, BCPPS (she/her/hers) – Riley Hospital for Children at Indiana University Health

  • 10:15 AM - 12:15 PM ET
    W28.3- Pharmacokinetics of elexacaftor/tezacaftor/ivacaftor with concomitant rifabutin

    Speaker: Madeline Sanders, BS – University of Southern California

  • 10:15 AM - 12:15 PM ET
    W28.4- Exploring Clinical Practices Regarding Highly Effective Modulator Therapy (HEMT) in Pregnancy and Postnatal Care

    Speaker: Sabrina Sherwood, PharmD, BCPS – St Lukes Cystic Fibrosis Center of Idaho

  • 10:15 AM - 12:15 PM ET
    W28.5- Management strategies for hepatotoxicity associated with elexacaftor/tezacaftor/ivacaftor: Results of a provider survey

    Speaker: Charissa Kam, PharmD, BCPPS, CPP (she/her/hers) – UNC Medical Center